Genvor Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Genvor Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $0 | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 28, 2023 |
| FY2021 | Sep 30, 2021 | $0 | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | $0 | Aug 2, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($5.59M) | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | ($2.88M) | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | ($1.71M) | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | ($4.24M) | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | ($3.44M) | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | ($23.8K) | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | ($4.9K) | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | ($6.0K) | Aug 2, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($6.41M) | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | ($2.78M) | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | ($1.44M) | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | ($4.06M) | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | ($3.10M) | Jan 16, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $455.9K | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | $240.3K | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | $0 | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | $0 | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | $226.4K | Jan 16, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $23.8K | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | $4.9K | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | $6.0K | Aug 2, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($555.7K) | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | ($975.6K) | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | $871.7K | Jan 16, 2024 |
| FY2023 | Sep 30, 2022 | ($553.2K) | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | ($663.2K) | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | $0 | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | $0 | Aug 2, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $45.8K | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | $35.6K | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | $82.1K | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | $316.0K | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | $556.9K | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | $0 | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | $0 | Aug 2, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.36M | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | $1.75M | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | $1.79M | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | $1.71M | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | $2.79M | Jan 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.31M) | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | ($1.71M) | Dec 10, 2025 |
| FY2025 | Sep 30, 2023 | ($1.70M) | Dec 10, 2025 |
| FY2023 | Sep 30, 2022 | ($1.39M) | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | ($2.24M) | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | ($27.7K) | Mar 21, 2022 |
| FY2022 | Dec 31, 2020 | ($1.59M) | Jan 16, 2024 |
| FY2021 | Sep 30, 2020 | ($17.3K) | Mar 21, 2022 |
| FY2022 | Dec 31, 2019 | ($1.56M) | Jan 16, 2024 |
| FY2021 | Sep 30, 2019 | ($15.8K) | Mar 21, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($26.19M) | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | ($20.60M) | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | ($17.72M) | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | ($16.04M) | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | ($11.80M) | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | ($64.5K) | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | ($40.7K) | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | ($35.8K) | Aug 2, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $0 | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Mar 21, 2022 |
| FY2020 | Sep 30, 2019 | $0 | Aug 2, 2021 |
| FY2020 | Sep 30, 2018 | $0 | Aug 2, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $20.0K | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | $904.5K | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | $1.32M | Jan 16, 2024 |
| FY2022 | Sep 30, 2022 | $1.14M | Jan 16, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | 0 | Aug 1, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Jan 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Jan 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 30.18M | Dec 10, 2025 |
| FY2025 | Sep 30, 2024 | 20.03M | Dec 10, 2025 |
| FY2023 | Sep 30, 2023 | 19.06M | Sep 9, 2025 |
| FY2023 | Sep 30, 2022 | 38.68M | Sep 9, 2025 |
| FY2022 | Dec 31, 2021 | 26.03M | Jan 16, 2024 |
| FY2021 | Sep 30, 2021 | 20.00M | Mar 21, 2022 |
| FY2021 | Jan 11, 2021 | 20.00M | Mar 21, 2022 |
| FY2021 | Sep 30, 2020 | 20.00M | Mar 21, 2022 |
| FY2021 | Sep 30, 2019 | 20.00M | Mar 21, 2022 |